Non-GAAP net gain due to 3SBio Inc. In the 4th quarter of 2011 improved by 34.3 percent to RMB22.3 million , compared to non-GAAP net income of RMB16.6 million in the fourth quarter of 2010. GAAP net income due to 3SBio Inc. Per ADS on a fully-diluted basis in the fourth one fourth of 2011 was RMB0.99 in comparison to a GAAP net income attributable to 3SBio Inc. Per ADS on a fully-diluted basis of RMB0.30 for the fourth quarter of 2010. Non-GAAP net income due to 3SBio Inc. Per ADS on a fully-diluted basis in the fourth one fourth of 2011 was RMB0.99 , compared to non-GAAP net income due to 3SBio Inc. Per Advertisements on a fully-diluted basis of RMB0.74 in the fourth quarter of 2010.IQWiG consequently downgrades the level of the added good thing about aflibercept in comparison to the appropriate comparator therapy from considerable to minor . IQWiG published a first assessment of aflibercept on 15th March 2013. This dealt with a different therapeutic indication, however, namely the treatment of wet age-related macular degeneration . G-BA chooses on the extent of added benefit The dossier evaluation is area of the overall procedure for early advantage assessments supervised by the G-BA. After publication of the manufacturer's IQWiG&# and dossier;s assessment, the G-BA conducts a commenting treatment, which may provide further information and result in a change to the benefit assessment. The G-BA decides on the degree of the added advantage then, completing the early benefit assessment thus.